• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Español
  • English
  • Bloglovin
  • Email
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube
CDE Almería – Centro de Documentación Europea – Universidad de Almería

CDE Almería - Centro de Documentación Europea - Universidad de Almería

Centro de Documentación Europea de la Universidad de Almería

  • HOME
  • WHAT´S ON
    • EU BULLETINS
    • EU NEWS
    • Activities
    • EU Calls and Awards
    • Radio Program «Europe with You»
  • DOCUMENTATION
    • Bibliographic Collection
      • Almería EDC Digital Collection
      • UNIVERSITY OF ALMERIA LIBRARY
    • Documentation by topic
    • EU Media Collection
      • Web Space
      • MEDIATHEQUE REPOSITORY
  • Europe on the net
    • Institutions
    • EU Representation in Spain
    • European information network of Andalusia
    • EU official journal
  • ABOUT US
    • Presentation
    • People
    • Contact

Epigenetic therapy! Switching off your own cancer genes

Inicio » EU News » Epigenetic therapy! Switching off your own cancer genes

22/03/2019

Cancer, particularly acute myeloid leukaemia (AML), is aggressive and also resistant to anti-cancer therapy, resulting in poor patient outcomes. Understanding how genes can be switched on and off without affecting their DNA sequence is paramount for the development of new anti-cancer therapies.

AML is characterised by the abnormal proliferation of immature myeloid cells. The standard of care for AML patients has not changed for many years, and the 5-year survival rate for AML patients is still only about 30%. Therefore, there is an urgent need to develop novel therapies for AML. Accumulating scientific evidence indicates a role for epigenetic changes in cancer onset and progression, and new therapies could therefore be based on targeting the epigenetic state of AML.

“Epigenetic regulators are frequently mutated in AML and represent good drug targets,″ explains project coordinator Prof. Kristian Helin. The EU-funded NovLeuReg project, a Marie Skłodowska-Curie fellowship grant, aimed to identify novel epigenetic regulators in AML to support the development of personalised treatments in the future.

To identify epigenetic regulators and investigate the molecular mechanisms behind them, scientists performed loss-of-function forward genetics screens. They used the CRISPR interference genome editing technology to generate a library capable of targeting 1 046 genes of all the known and putative chromatin-associated proteins.

The future of epigenetics therapy

Collectively, the work by NovLeuReg alongside technological advancement provides novel knowledge in the field of malignant haematopoiesis. The identification of these new proteins that contribute to AML development and maintenance sheds new light into the process and mechanism underlying leukemogenesis and unveils novel therapeutic targets.

Overall, the reversible nature of epigenetic marks has raised optimism for the development of new therapies in leukaemia by pharmacological inhibition of chromatin-modifying enzymes. New therapies are much needed for this type of cancer that presents with high mortality rates and no unified treatment. Long-term, it will be possible to develop personalised therapies for AML patients following detailed molecular analysis of leukemic cells.

More Information

Access to the complete news 

Publicaciones relacionadas:

€2 billion to fast forward the creation of the European Innovation Council Imminent anti-metastatic vaccine for prostate cancer New technology is recognising affective states R&I cooperation between EU and Middle East reaches new heights A week of events open to citizens will focus on future EU research and scientific excellence

“This is a space for debate. All comments, for or against publication, that are respectful and do not contain expressions that are discriminatory, defamatory or contrary to current legislation will be published”.

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Primary Sidebar

Publicaciones relacionadas

€2 billion to fast forward the creation of the European Innovation Council Imminent anti-metastatic vaccine for prostate cancer New technology is recognising affective states R&I cooperation between EU and Middle East reaches new heights A week of events open to citizens will focus on future EU research and scientific excellence

Footer

Centro de Documentación Europea de Almería
CDE Almería

Edificio Parque Científico-Tecnológico (Pita) Planta: 1ª, Despacho: 29
04120 – Ctra. Sacramento s/n.
Almería (Spain)
Teléfono: (+34) 950 015266

Sing in!

Navigation

  • HOME
  • WHAT´S ON
    • EU BULLETINS
    • EU NEWS
    • Activities
    • EU Calls and Awards
    • Radio Program «Europe with You»
  • DOCUMENTATION
    • Bibliographic Collection
      • Almería EDC Digital Collection
      • UNIVERSITY OF ALMERIA LIBRARY
    • Documentation by topic
    • EU Media Collection
      • Web Space
      • MEDIATHEQUE REPOSITORY
  • Europe on the net
    • Institutions
    • EU Representation in Spain
    • European information network of Andalusia
    • EU official journal
  • ABOUT US
    • Presentation
    • People
    • Contact

Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright © 2022 CDE Almería · Legal terms · Privacy policy · Cookies policy